| Model Number |
9004 |
| Medical Device Problem Code |
Adverse Event Without Identified Device or Use Problem (2993)
|
| Health Effect - Clinical Code |
Reocclusion (1985)
|
| Date of Event |
02/22/2017
|
|
Type of Reportable Event
|
Serious Injury
|
|
Additional Manufacturer Narrative
|
|
Analysis: the sample was not returned from the user facility; therefore, a device evaluation is unable to be performed.A lot history review revealed this is the only complaint associated with this lot.A review of the device history record (dhr) indicates the lot was manufactured to specification.Conclusion: the actual sample was not returned for evaluation.The dhr found nothing to indicate a manufacturing related cause for this event.The investigator assessed the event was not related to the study device or procedure.Based on the instructions for use (ifu), the occurrence of reocclusion is an inherent risk of any pta procedure, and has been reported in clinical trials of drug coated balloons.If additional information becomes known to the manufacturer, a supplemental report will be provided with all relevant information.
|
| |
|
Event or Problem Description
|
|
It was reported through a clinical registry that during the index procedure, a lutonix percutaneous transluminal drug coated balloon (dcb) dilatation catheter was used to treat the target lesion located in right proximal popliteal artery.Approximately 10 months after the index procedure, the patient¿s right proximal popliteal artery was reportedly reoccluded via duplex ultrasound (dus) imaging.Approximately 28 months after the index procedure, a revascularization was performed and the health care professional (hcp) deemed it was successful.The investigator assessed the event was not related to the study device or to the procedure.The sample was discarded by the user facility and is not available for further evaluation.No adverse patient effects were reported.
|
| |
|
Event or Problem Description
|
|
It was reported through a clinical registry that during the index procedure, a lutonix percutaneous transluminal drug coated balloon (dcb) dilatation catheter was used to treat the target lesion located in right proximal popliteal artery.Approximately 10 months after the index procedure, the patient¿s right proximal popliteal artery was reportedly reoccluded via duplex ultrasound (dus) imaging.Approximately 28 months after the index procedure, a revascularization was performed and the health care professional (hcp) deemed it was successful.The investigator assessed the event was not related to the study device or to the procedure.The sample was discarded by the user facility and is not available for further evaluation.No adverse patient effects were reported.
|
| |
|
Additional Manufacturer Narrative
|
|
Corrected data: relevant tests/laboratory data.The relevant tests and lab data had the non-target vessel revascularization date changed from "on (b)(6) 2019" to "on (b)(6) 2018".Device evaluated by mfr analysis: the sample was not returned from the user facility; therefore, a device evaluation is unable to be performed.A lot history review revealed this is the only complaint associated with this lot.A review of the device history record (dhr) indicates the lot was manufactured to specification.Conclusion: the actual sample was not returned for evaluation.The dhr found nothing to indicate a manufacturing related cause for this event.The investigator assessed the event was not related to the study device or procedure.Based on the instructions for use (ifu), the occurrence of reocclusion is an inherent risk of any pta procedure, and has been reported in clinical trials of drug coated balloons.If additional information becomes known to the manufacturer, a supplemental report will be provided with all relevant information.
|
| |
|
Search Alerts/Recalls
|